This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue reporting for Medscape. Joining me today is Dr Sahil Parikh, who's a cardiologist and an interventionalist at Columbia University. He's an associate professor of medicine.
We'll be discussing two interesting trials that were presented at the ESC Congress here in Amsterdam. They do have the potential to be very practice-changing, so I think it's worth talking about.
The FIRE Trial
The first trial we'll be talking about is the FIRE trial. Perhaps setting the stage, Sahil, I'd love to get your thoughts. We've had data in this space to suggest that, for patients with STEMI [ST-segment elevation myocardial infarction], a strategy of complete revascularization — and not only treating the culprit lesion but also treating additional lesions — may be of benefit. Where does that lead us in terms of what we didn't know?
Sahil A. Parikh, MD: I think that the practice has moved, at least in the United States, over the past two decades, from staging percutaneous coronary interventions (PCIs) over 30 days from index to intervention to now trying to do patients in the same hospitalization whenever possible to achieve complete revascularization.
COMMENTARY
Is Complete Revascularization Now Compulsory? MULTISTARS-AMI and FIRE in Context
Michelle L. O'Donoghue, MD, MPH; Sahil A. Parikh, MD
DisclosuresSeptember 08, 2023
This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue reporting for Medscape. Joining me today is Dr Sahil Parikh, who's a cardiologist and an interventionalist at Columbia University. He's an associate professor of medicine.
We'll be discussing two interesting trials that were presented at the ESC Congress here in Amsterdam. They do have the potential to be very practice-changing, so I think it's worth talking about.
The FIRE Trial
The first trial we'll be talking about is the FIRE trial. Perhaps setting the stage, Sahil, I'd love to get your thoughts. We've had data in this space to suggest that, for patients with STEMI [ST-segment elevation myocardial infarction], a strategy of complete revascularization — and not only treating the culprit lesion but also treating additional lesions — may be of benefit. Where does that lead us in terms of what we didn't know?
Sahil A. Parikh, MD: I think that the practice has moved, at least in the United States, over the past two decades, from staging percutaneous coronary interventions (PCIs) over 30 days from index to intervention to now trying to do patients in the same hospitalization whenever possible to achieve complete revascularization.
© 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Is Complete Revascularization Now Compulsory? MULTISTARS-AMI and FIRE in Context - Medscape - Sep 08, 2023.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Michelle L. O'Donoghue, MD, MPH
Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School; Associate Physician, Brigham and Women's Hospital, Boston, Massachusetts
Disclosure: Michelle L. O'Donoghue, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Janssen; Novartis; CVS Minute Clinic
Received research grant from: Merck & Co., Inc.; GlaxoSmithKline; Eisai Inc.; AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; Medicines Company; Amgen
The opinions expressed in this article are solely my own and do not necessarily reflect the views and opinions of Brigham and Women's Hospital.
Sahil A. Parikh, MD
Associate Professor of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons; Director, Endovascular Services, Columbia University Irving Medical Center, New York, NY
Disclosure: Sahil A. Parikh, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; Boston Scientific; Medtronic; Cordis; Phillips; Terumo, Inari; Penumbra; Canon Received research grant from: Abbott; Boston Scientific; Shockwave Medical; Concept Medical; Acotec